PT  - JOURNAL ARTICLE
AU  - TATSUYA YOSHIDA
AU  - KIYOTAKA YOH
AU  - KOICHI GOTO
AU  - SEIJI NIHO
AU  - SHIGEKI UMEMURA
AU  - HIRONOBU OHMATSU
AU  - YUICHIRO OHE
TI  - Safety and Efficacy of Platinum Agents plus Etoposide for Patients with Small Cell Lung Cancer with Interstitial Lung Disease
DP  - 2013 Mar 01
TA  - Anticancer Research
PG  - 1175--1179
VI  - 33
IP  - 3
4099  - http://ar.iiarjournals.org/content/33/3/1175.short
4100  - http://ar.iiarjournals.org/content/33/3/1175.full
SO  - Anticancer Res2013 Mar 01; 33
AB  - Background: The safety and efficacy of combination of platinum agents plus etoposide for patients with small cell lung cancer (SCLC) with pre-existing interstitial lung disease (ILD) is uncertain. Patients and Methods: Fifty-two patients received platinum agents plus etoposide as first-line chemotherapy for SCLC with pre-existing ILD. The clinical characteristics, treatment outcome and survival of these patients were retrospectively reviewed. Results: During first-line chemotherapy, only one (2%) out of the 52 patients developed an acute exacerbation of ILD. The median number of treatment cycles was four. The overall response rate was 69%. The median progression-free survival period was 4.5 months. The median survival time was 9.4 months. Thirty-three patients (63%) received at least one subsequent chemotherapy regimen, and five of these patients developed acute exacerbation of ILD. Conclusion: The combination of platinum agents plus etoposide is feasible and effective in SCLC patients with pre-existing ILD, compared with regimens after second-line chemotherapy.